STOCK TITAN

Jorey Chernett reports 14.1% Neuronetics (STIM) holding in 13D

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Jorey Chernett filed a Schedule 13D reporting a large stake in Neuronetics, Inc. He beneficially owns 9,778,718 shares of common stock, representing about 14.12% of the 69,276,593 shares outstanding as of March 10, 2026.

The shares were acquired in private transactions using personal funds totaling $19,557,436. Chernett holds sole voting and dispositive power over all reported shares and describes himself as a private investor who believed the stock was undervalued when purchased. He currently has no specific plans for corporate actions but may buy or sell more shares and may engage with management, the board, and other stockholders about strategy, capital structure, governance, or potential business combinations.

Positive

  • None.

Negative

  • None.

Insights

Private investor discloses a 14.12% Neuronetics stake, signaling potential future engagement.

Jorey Chernett now beneficially owns 9,778,718 Neuronetics shares, or about 14.12% of the company, acquired for $19,557,436 through private transactions. That size makes him a significant shareholder with sole voting and dispositive power over the stake.

The filing states he bought the shares believing they were undervalued and that he has no present concrete plans for corporate actions tied to specific restructuring, transactions, or governance changes. However, the disclosure lists a wide range of possible future steps, from buying or selling more stock to discussing strategy, capitalization, board composition, or potential business combinations.

This language is typical of an investor keeping options open rather than committing to a defined campaign. The impact for other shareholders will depend on whether he later pursues actions like board changes or transaction proposals, which would be reflected in subsequent filings and company communications.

Shares beneficially owned 9,778,718 shares Neuronetics common stock beneficially owned as of March 31, 2026
Ownership percentage 14.12% Percent of Neuronetics common stock based on 69,276,593 shares outstanding as of March 10, 2026
Shares outstanding 69,276,593 shares Neuronetics common shares outstanding as of March 10, 2026
Purchase amount $19,557,436 Personal funds used by Chernett to acquire 9,778,718 shares in private transactions
Sole voting power 9,778,718 shares Shares over which Chernett has sole power to vote or direct the vote
Sole dispositive power 9,778,718 shares Shares over which Chernett has sole power to dispose or direct disposition
Schedule 13D regulatory
"This represents the initial statement on filed by the Reporting Person with the Securities and Exchange Commission with respect to shares of the Issuer and amends and supersedes the Schedule 13G."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
beneficially owned financial
"As of the close of business on March 31, 2026, the Reporting Person beneficially owned 9,778,718 Shares."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power financial
"Sole Voting Power 9,778,718.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Sole Dispositive Power 9,778,718.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
private transactions financial
"The 9,778,718 Shares held by Mr. Chernett were acquired through private transactions using personal funds in the amount of $19,557,436."
contracts, arrangements, understandings or relationships regulatory
"Other than as escribed herein, the Reporting Person does not have any other contracts, arrangements, understandings or relationships with respect to the Issuer's securities."





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D


Chernett Jorey
Signature:/s/ Jorey Chernett
Name/Title:Jorey Chernett
Date:03/31/2026

FAQ

What stake did Jorey Chernett report in Neuronetics (STIM)?

Chernett reported beneficial ownership of 9,778,718 Neuronetics shares, representing approximately 14.12% of the outstanding common stock based on 69,276,593 shares outstanding as of March 10, 2026. This makes him a significant shareholder with sole voting and dispositive power over the reported shares.

How much did Jorey Chernett invest in Neuronetics (STIM) shares?

He acquired the 9,778,718 shares through private transactions using personal funds totaling $19,557,436. The filing describes him as a private investor who believed the shares were undervalued when purchased, framing the position as an investment rather than a purely passive holding.

Why did Jorey Chernett file a Schedule 13D for Neuronetics (STIM)?

He crossed the threshold requiring a Schedule 13D after building a 14.12% stake, previously reported on Schedule 13G. The new filing reflects a more active posture, allowing for potential future actions such as engaging management, discussing strategy, or changing his ownership level.

Does Jorey Chernett have control over his Neuronetics (STIM) shares?

Yes. The filing shows sole voting power and sole dispositive power over all 9,778,718 reported shares, with no shared voting or dispositive authority. This means he alone decides how those shares are voted and whether, when, and how they are sold or otherwise disposed of.

What future actions does Jorey Chernett contemplate regarding Neuronetics (STIM)?

He may buy more or sell some or all shares, and might communicate with management, the board, or other stockholders about capitalization, ownership structure, board composition, or potential business combinations. The filing stresses he currently has no specific plans but intends to review the investment on an ongoing basis.

How many Neuronetics (STIM) shares were outstanding for this 13D calculation?

The 14.12% ownership figure is based on 69,276,593 Neuronetics common shares outstanding as of March 10, 2026, as disclosed in the company’s Form S-3 registration statement filed March 17, 2026. Chernett’s beneficial ownership percentage is calculated using that share count.
Neuronetics

NASDAQ:STIM

View STIM Stock Overview

STIM Rankings

STIM Latest News

STIM Latest SEC Filings

STIM Stock Data

89.37M
27.90M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MALVERN